Pfizer’s Vyndaqel Splits Advisory Committee; Now It Must Move FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
In mirror-image votes, FDA’s Peripheral and Central Nervous System Drugs Advisory Committee says that there is substantial evidence for surrogate endpoints but not for clinical endpoints for the drug to treat familial amyloid polyneuropathy.